Aphria Inc. (NYSE: APHA, TSX: APH) was founded in 2014 and is headquartered in Leamington, Canada, with 300 full-time employees. It is a company that produces, supplies and sells medical marijuana in Canada.
Aphria Inc. (APHA):
Aphria is a Canadian medical cannabis company listed on the Toronto Stock Exchange (APH) and the New York Stock Exchange (APHA), and is one of the largest cannabis companies in Canada. Averyia means “pleasant” in Celtic.
Aphria is truly “powered by sunlight”, producing safe medical cannabis products under the most natural growth conditions. Aphria promises: 100% greenhouse cultivation, product safety, constant quality, and excellent patient care.
Averya provides sativa, indica and hybrid medical cannabis products, as well as cannabis oil; it also provides medical consultation, group therapy and rehabilitation services for veterans and emergency personnel.
Aphria sells its products through its online store or phone, and is engaged in the wholesale transportation of branches and dried buds of medical marijuana plants and sells them to other licensed manufacturers.
Aphria operates a greenhouse in Lymington, Ontario that produces hemp.
Aphria Inc. (APHA) History:
- In 2014, Leamington’s greenhouse operators Cole Cacciavillani and John Cervini founded Aphria Inc., the company’s CEO Vic Neufeld is the former CEO of Canadian vitamin producer Jamieson Laboratories.
- The company initially landed on the Toronto Venture Exchange and transferred to the Toronto Stock Exchange in March 2017. It became a constituent stock of the S&P/TSX Composite Index in December of the same year.
- In April 2015, the company completed its first wholesale business; also in April, Aphria announced that it would double the size of its greenhouse.
- In 2016, Aphria announced a collaboration with Toronto Lifestyle brand Tokyo Smoke.
- In April 2017, Aphria announced its expansion strategy in the United States. There are concerns that Aphria may be delisted from the Toronto Stock Exchange or face other sanctions because the legal status of US cannabis is uncertain.
- In December 2017, Aphria announced that Shoppers Drug Mart, a Canadian pharmacy, would sell its products online.
- In January 2018, Aphria agreed to acquire Vancouver Island cannabis producer Broken Coast Cannabis for $230 million in cash and stock.
- Also in January 2018, Aphria agreed to acquire Nuuvera, a cannabis company located in Brampton, for US$826 million. The company is mainly interested in Nuuvera’s markets in Germany and Italy. However, due to the decline in Aphria’s stock price, when the transaction was completed in March 2018, the transaction value was only $425 million. In addition, due to the undisclosed ownership stakes of several Aphria insiders in Nuuvera, some controversies have arisen, which they did not disclose.
- In May 2018, Aphria reached an agreement with Southern Glazer’s Wine & Spirits to distribute Aphria’s recreational hemp products in Canada for the company.
- In July 2018, Aphria announced that it would acquire several South American cannabis companies with Scythian Biosciences for approximately US$200 million. Scythian Biosciences is a company closely related to Aphria, sometimes referred to as Aphria’s acquisition unit.
- In November 2018, Aphria transferred from OTC to NYSE trading in the US market, and its stock code was changed from OTC: APHQF to NYSE: APHA.
Aphria Inc. (APHA) investment:
Other companies in the same industry include : Canopy Growth Corporation (CGC) , Aurora Cannabis Inc. (ACB) , Cronos Group Inc. (CRON), etc.